Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a standalone product or in combination with conventional...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Hum Vaccin Immunother
Auteurs principaux: Seid, Christopher A., Jones, Kathryn M., Pollet, Jeroen, Keegan, Brian, Hudspeth, Elissa, Hammond, Molly, Wei, Junfei, McAtee, C. Patrick, Versteeg, Leroy, Gutierrez, Amanda, Liu, Zhuyun, Zhan, Bin, Respress, Jonathan L., Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J.
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2016
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360114/
https://ncbi.nlm.nih.gov/pubmed/27737611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1242540
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires